Affiliation: Uppsala University Hospital
- In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancerYlva Almqvist
Division of Radiology, Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden
Nucl Med Biol 33:991-8. 2006..The aim of this study was to determine the biodistribution and tumor-targeting ability of (177)Lu-labeled huA33...
- In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinomaYlva Almqvist
Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Uppsala, Sweden
Cancer Biother Radiopharm 20:514-23. 2005..The (211)At-A33 conjugate shows promise as a potential radioimmunotherapy agent for treatment of micrometastases originating from colorectal carcinoma...
- Biodistribution of 211At-labeled humanized monoclonal antibody A33Ylva Almqvist
Unit of Radiology, Department of Oncology, Radiology, and Clinical Immunology, Uppsala University, Sweden, and Department of Clinical Physiology and Nuclear Medicine, PET and Cyclotron Unit, Rigshospitalet, Copenhagen, Denmark
Cancer Biother Radiopharm 22:480-7. 2007..In conclusion, the favorable biodistribution and specific in vivo targeting ability of 211At-huA33 makes it a potential therapeutic agent for the RIT of metastatic colorectal carcinoma...
- Combined effect of gefitinib ('Iressa', ZD1839) and targeted radiotherapy with 211At-EGFAsa Liljegren Sundberg
Division of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
Eur J Nucl Med Mol Imaging 30:1348-56. 2003..These results indicate that combined treatment with gefitinib might increase the effect of ligand-mediated radionuclide therapy in gefitinib-resistant tumours and decrease the effect of such therapy in gefitinib-sensitive tumours...
- Biodistribution of 211At labeled HER-2 binding affibody molecules in miceAnn Charlott Steffen
Unit of Biomedical Radiation Sciences, Department of Oncology, Rudbeck Laboratory, Uppsala University, SE 751 85 Uppsala, Sweden
Oncol Rep 17:1141-7. 2007..However, the labeling chemistry affects the distribution in normal organs to a high degree and needs to be improved to allow clinical use...
- Treatment of cultured glioma cells with the EGFR-TKI gefitinib ("Iressa", ZD1839) increases the uptake of astatinated EGF despite the absence of gefitinib-mediated growth inhibitionAsa Liljegren Sundberg
Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden
Eur J Nucl Med Mol Imaging 30:727-9. 2003..This indicates that a combination of gefitinib treatment and radionuclide targeting to EGFR might be a useful therapeutic modality, even for patients who do not respond to treatment with gefitinib alone...
- [99mTc] HYNIC-hEGF, a potential agent for imaging of EGF receptors in vivo: preparation and pre-clinical evaluationMohammad Hossein Babaei
Radioisotope Division, Nuclear Research Center, Atomic Energy Organisation of Iran, Tehran, Iran
Oncol Rep 13:1169-75. 2005..Biodistribution of (99m)Tc-EDDA-HYNIC-EGF in normal mice demonstrated fast blood clearance of conjugate, and its ability to bind EGFR in vivo. (99m)Tc-EDDA-HYNIC-EGF is a promising candidate for visualization of EGFR expression in vivo...